Section

Medicine

Trials, therapies, and evidence that changes care.

Daily at 06:15 UTC

Edition No. 3
Updated UTC

Top stories

  1. 1. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND

    Objective In prespecified analyses, the treatment effect for major adverse cardiovascular event (MACE) of tirzepatide compared with imputed placebo was estimated using SURPASS-Cardiovascular Outcomes Trial…

    ██████░░░░5.5
  2. 2. Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial

    Background WHO grade 2 atypical meningioma is a primary brain tumour with a high risk of recurrence even after complete surgical resection.

    █████░░░░░5.3
  3. 3. Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial

    Background Vitamin C (VitC) is a cofactor for TET enzymes involved in DNA demethylation and epigenetic regulation.

    █████░░░░░5.3

More top stories

No.04 to No.06

Briefs

8 more from the desk